Oral pioglitazone administration increases food intake through ghrelin-independent pathway in Zucker fatty rat

Diabetes Research and Clinical Practice

Volumn 77, Issue 3, 2007, Pages 351-356

  Saitoh, Yukie ^a   Liu, Runhua ^a   Ueno, Hiroaki ^a   Mizuta, Masanari ^a   Nakazato, Masamitsu ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Food comsumption; Ghrelin; Thiazolidindiones; Weight gain

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; GHRELIN; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; ENERGY EXPENDITURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID BLOOD LEVEL; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RADIOIMMUNOASSAY; RAT; TREATMENT OUTCOME; WEIGHT GAIN; ZUCKER DIABETIC FATTY RAT;

ANIMALS; BODY WEIGHT; EATING; ENERGY METABOLISM; GHRELIN; HYPOGLYCEMIC AGENTS; RATS; RATS, ZUCKER; THIAZOLIDINEDIONES;

EID: 34547665561     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.01.016     Document Type: Article

References (38)

1. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B.T., Rabinowitz D., et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269 (1995) 543-546
2. Phillips M.S., Liu Q., Hammond H.A., Dugan V., Hey P.J., Caskey C.J., et al. Leptin receptor missense mutation in the fatty Zucker rat. Nat. Genet. 13 (1996) 18-19
3. Couillard C., Mauriege P., Imbeault P., Prud'homme D., Nadeau A., Tremblay A., et al. Hyperleptmemia is more closely associated with adipose cell hypertrophy than with adipose tissue Hyperplasia. Int. J. Obes. Relat. Metab. Disord. 24 (2000) 782-788
4. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
5. Asakawa A., Inui A., Kaga T., Yuzuriha H., Nagata T., Ueno N., et al. Ghrelin is anappetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120 (2001) 337-345
6. Masuda Y., Tanaka T., Inomata N., Ohnuma N., Tanaka S., and Itoh Z. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. 276 (2000) 905-908
7. Shiiya T., Nakazato M., Mizuta M., Date Y., Mndal M.S., Tanaka M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J. Clin. Endocrinol. Metab. 87 (2002) 240-244
8. Tamas L.H., Sabrina D., Peter S., Mark H., and Matthias T. Minireview: Ghrelin and the regulation of energy balance-A hypothalamic perspective. Endocrinology 142 (2001) 4163-4169
9. Nagaya N., Uematsu M., Kojima M., Ikeda Y., Yoshihara F., Shimizu W., et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104 (2001) 1430-1435
10. Toshinai K., Mondal M.S., Nakazato M., Date Y., Murakami N., Kojima M., et al. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem. Biophys. Res. Commun. 281 (2001) 1220-1225
11. Tschop M., Smiley D.L., and Heiman M.L. Ghrelin induces adiposity in rodents. Nature 407 (2000) 908-913
12. Burkey B.F., Dong M., Gagen K., Eckhardt M., Dragonas N., Chen W., et al. Pioglitazone promotes energy storage and not expenditure in brown dipose tissue of obese fa/fa Zucker rats: comparison with CL316, 243. Metabolism 49 (2000) 1301-1308
13. Wang Q., Dryden S., Frankish H.M., Bing C., Pickavance L., Hopkins D., et al. Increased feeding in fatty Zucker rats by the thaizoli-dindione BRL 49653 (rosiglitazone) and the possible involnement of leptin and hypothalamic neuropeptide Y. Br. J. Pharm. 122 (1997) 1405-1410
14. Okuno A., Tamemoto H., Tobe K., Ueki K., Mori Y., Iwamoto K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101 (1998) 1354-1361
15. Hallakou S., Doare L., Foufelle F., Kergoat M., Guerre-Millo M., Berthault M.F., et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46 (1997) 1393-1399
16. Kelly I.E., Walsh K., Han T.S., and Lean M.E.J. Effects of a thiazolidinedione compound on body fat and fat distribution on patients with type 2 diabetes. Diab. Care 22 (1999) 288-293
17. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., et al. Effects of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 87 (2002) 2784-2791
18. Weir B.J. Mew methods for calculating metabolic rate with special reference to protein metabolism. J. Physiol. 109 (1949) 1-9
19. Allison D.B., Paultre F., Maggio C., Mezzitis N., and Pi-Sunyer F.X. The use of areas under curves in diabetes research. Diab. Care 18 (1995) 245-250
20. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPAR γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
21. Masuzaki H., Ogawa Y., Isse N., Satoh N., Okazaki T., Shigemoto M., et al. Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue. Diabetes 44 (1995) 855-858
22. de Souza C.J., Eckhardt M., Gagen K., Dong M., Chen W., Laurent D., et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50 (2001) 1863-1871
23. Wren A.M., Small C.J., Abbott C.R., Dhillo W.S., Seal L.J., Cohen M.A., et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 50 (2001) 2540-2547
24. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., et al. A role foGhrelin in the central regulation of feeding. Nature 409 (2001) 194-198
25. Hosoda H., Kojima M., Matsuo H., and Kangawa K. Ghrelin and des-acyl ghrelin. Two major forms of rat ghrelin peptide in gastrointestimal tissue. Biochem. Biophys. Res. Commuun. 279 (2000) 909-913
26. Akamizu T., Shinomiya T., Irako T., Fukunaga M., Nakai Y., Nakai Y., et al. Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J. Clin. Endocrinol. Metab. 90 (2005) 6-9
27. Tschop M., Smiley D., and Heiman M.L. Ghrelin induces adiposity in rodents. Nature 407 (2000) 908-913
28. Shintani M., Ogawa Y., Ebihara K., Aizawa-Abe M., Miyanaga F., Takaya K., et al. Ghrelin, an endogeneous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50 (2001) 227-232
29. Lee H.M., Wang G., Englander E.W., Kojima M., George H., Greeley J., et al. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion, enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 143 (2002) 185-190
30. Pontiroli A.E., Lanzi R., Monti L.D., and Pozza G. Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects. J. Endocrinol. Invest. 13 (1990) 539-542
31. Mori Y., Murakawa Y., Okada K., Horikoshi H., Yokoyama J., Yajima N., et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diab. Care 22 (1999) 908-912
32. Kelly I.E., Walsh K., Han T.S., and Lean M.E.J. Effect of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diab. Care 22 (1999) 288-293
33. Ananda B., Michael D.J., Frances M.C., Debabrata M., Michael J.J., and Robert A.R. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diab. Care 22 (1999) 288-293
34. Foellmi-Adams L.A., Wyse B.M., Herron D., Nedergaard J., and Kletzien R.F. Induction of uncoupling protein in brown adipose tissue. Biochem. Pharmacol. 52 (1996) 693-701
35. Paulik M.A., and Lenhard J.M. Thiazolidindiones inhibit alkaline phosphate activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10Tl/2cells. Cell Tissue Res. 290 (1997) 79-87
36. Digby J.E., Montague C.T., and Sewter C.P. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes 47 (1998) 138-141
37. Tai T.A., Jennermann C., Brown K.K., Oliver B.B., MacGinnitie M.A., Wilkison W.O., et al. Activation of the nuclear receptor peroxisome proliferator-activated receptor γ promotes brown adipocyte differentiation. J. Biol. Chem. 271 (1996) 29909-29914
38. Aubert J., Champigny O., Saint-Marc P., Negrel R., Collins S., Ricquir D., et al. Up-regulation of UCP-2 gene expression by PPAR agonist in preadipose and adipose cells. Biochem. Biophys. Res. Commun. 238 (1997) 606-611